4//SEC Filing
Fitzgerald Thomas A 4
Accession 0001104659-22-029439
CIK 0001829635other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 6:12 PM ET
Size
5.7 KB
Accession
0001104659-22-029439
Insider Transaction Report
Form 4
Fitzgerald Thomas A
DirectorVP, Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-03-01+52,000→ 52,000 totalExercise: $2.12Exp: 2032-02-29→ Common Stock (52,000 underlying)
Footnotes (1)
- [F1]Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (February 1, 2022). Thereafter, the remaining Stock Options shall vest and become exercisable in twenty-four (24) equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.
Documents
Issuer
Transcode Therapeutics, Inc.
CIK 0001829635
Entity typeother
Related Parties
1- filerCIK 0001854168
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 6:12 PM ET
- Size
- 5.7 KB